CSV October 31, 2022 through October 31, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DICYCLOMINE IDENTIFICATIO		*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *B.*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE								*Identification Tests—General* ?191?, *Chemical Identification Tests*, *Chloride*: Change Meets the requirements when tested as specified in test *B*. to: Meets the requirements of the test for amine hydrochlorides
AMOXICILLIN ORAL SUSPENSION	IDENTIFICATION	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	Change Shake a portion of Oral Suspension with a mixture of acetone and 0.1 N hydrochloric acid (4:1) to obtain a solution containing about 1 mg of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								amoxicillin per mL. The solution responds to the *Identification* test under *Amoxicillin Capsules*. to: Prepare a test solution by shaking a portion of Oral Suspension with a mixture of acetone and 0.1 N hydrochloric acid (4:1) to obtain a solution containing about 1 mg of amoxicillin per mL. Prepare a Standard solution of USP Amoxicillin RS in 0.1 N hydrochloric acid containing

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1 mg per mL. Use within 10 minutes after preparation. Apply separately 5 µL of each solution on a thin-layer chromatographic plate coated with a 0.25-mm layer of chromatographic silica gel mixture (see *Chromatography* ?621?). Place the plate in a suitable chromatographic chamber, and develop the chromatogram in a solvent system consisting of a mixture of methanol, chloroform, water, and pyridine (90:80:30:10).

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								When the solvent front has moved about three-fourths of the length of the plate, remove the plate from the chamber, and dry with warm air for 10 minutes. Locate the spots on the plate by spraying lightly with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry at 110° for 15 minutes: the R_F value of the principal spot obtained from the test solution corresponds to that obtained from the Standard solution.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LINEZOLID TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *Dissolution* ?711?/*Test 1*/*Analysis*: Change Result = $(r_U/r_S) \times C_S \times V \times (1/L) \times 100$ r_U = peak response of linezolid from the *Sample solution* r_S = peak response of linezolid from the *Standard solution* C_S = concentration of USP Linezolid RS in the *Standard solution* (mg/mL) V = volume of *Medium*, 900 mL L = label claim (mg/Tablet) to: Result = (*r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U/r_S$) × C_S × V × (1/L) × D × 100 r_U = peak response of linezolid from the *Sample solution* r_S = peak response of linezolid from the *Standard solution* C_S = concentration of USP Linezolid RS in the *Standard solution* (mg/mL) V = volume of *Medium*, 900 mL L = label claim (mg/Tablet) D = dilution factor of the *Sample solution*, as needed
CARVEDILOL	PERFORMANC	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *Dissolution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	E TESTS							<711>/*Test 3*/ *Chromatographic system*/*Column*: Change 4.6-mm × 15-mm; 5-?m packing L7 to: 4.6-mm × 15-cm; 5-?m packing L7
THEOPHYLLINE CAPSULES	IDENTIFICATION	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	Change **A:** The contents of the Capsules respond to *Identification* tests *A* and *B* under *Theophylline Tablets*. **B:** The retention time of the major peak in the chromatogram of the *Assay preparation* corresponds to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								that in the chromatogram of the *Standard preparation*, as obtained in the *Assay*. to: **A:** Triturate a quantity of the contents of Capsules, equivalent to about 500 mg of theophylline, with 10-mL and 5-mL portions of solvent hexane, and discard the solvent hexane. Triturate the residue with two 10-mL portions of a mixture of equal volumes of 6 N ammonium hydroxide and water, and filter each time. Evaporate the combined

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								filtrates to about 5 mL, neutralize, if necessary, with 6 N acetic acid, using litmus, and then cool to about 15°, with stirring. Collect the precipitate on a filter, wash it with cold water, and dry at 105° for 2 hours: the theophylline so obtained melts between 270° and 274° (see *Melting Range or Temperature* ?741?, *Procedures*, *Procedure for Class I*). Retain the remaining portion of the theophylline for use in *Identification* test *B*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								B: The IR absorption spectrum of a potassium bromide dispersion of the residue obtained in *Identification* test *A* exhibits maxima only at the same wavenumbers as that of a potassium bromide dispersion of USP Theophylline RS. **C:** The retention time of the major peak in the chromatogram of the *Assay preparation* corresponds to that in the chromatogram

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of the *Standard preparation*, as obtained in the *Assay*.
ACARBOSE	IMPURITIES	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In *Chromatographic Purity/Analysis*: Change Result = $(r_U/r_A) \times (1/F) \times 100$ to: Result = $(r_U/r_A) \times (1/F)$
GLUCAGON	PROCESS-RELATED IMPURITIES AND OTHER COMPONENTS	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In *Acetic Acid in Peptides/Analysis*: Change C_{SPA} = concentration of potassium acetate in each of the *Standard solutions* (mg/mL) to: C_{SPA} = concentration of potassium acetate in each of the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solutions (µg/mL) AND In *Ammonium/ Analysis*: Change C_{SAC} = concentration of ammonium chloride in each of the *Standard solutions* (mg/mL) to: C_{SAC} = concentration of ammonium chloride in each of the *Standard solutions* (µg/mL)
ANTIBIOTICS—APPENDICES MICROBIAL ASSAYS		*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In two instances in *Appendix 1* equations: Change 14.020 to: 14.022
SECOBARBITA	OTHER REQUI	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
L SODIUM	REMENTS							Where the label states that Secobarbital Sodium is sterile, it meets the requirements for *Sterility Tests* ?71? and for *Bacterial endotoxins* under *Secobarbital Sodium for Injection*. Where the label states that Secobarbital Sodium must be subjected to further processing during the preparation of injectable dosage forms, it meets the requirements for *Bacterial endotoxins* under *Secobarbital*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sodium for Injection. to: Where the label states that Secobarbital Sodium is sterile, it meets the requirements for *Sterility Tests* ?71? and the level of bacterial endotoxins is not more than 0.9 USP Endotoxin Units per mg of secobarbital sodium tested per *Bacterial Endotoxins Test* <85>. Where the label states that Secobarbital Sodium must be subjected to further processing

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								during the preparation of injectable dosage forms, the level of bacterial endotoxins is not more than 0.9 USP Endotoxin Units per mg of secobarbital sodium tested per *Bacterial Endotoxins Test* <85>.
AMOXICILLIN INTRAMAMMARY INFUSION	IDENTIFICATION	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	Change The solution obtained responds to the *Identification* test under *Amoxicillin Capsules*. to: Prepare a Standard solution of USP Amoxicillin RS in 0.1 N hydrochloric

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acid containing 4 mg per mL. Use within 10 minutes after preparation. Apply separately 5 µL of each solution on a thin-layer chromatographic plate coated with a 0.25-mm layer of chromatographic silica gel mixture (see *Chromatography* <621>). Place the plate in a suitable chromatographic chamber, and develop the chromatogram in a solvent system consisting of a mixture of methanol, chloroform, water, and pyridine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(90:80:30:10). When the solvent front has moved about three-fourths of the length of the plate, remove the plate from the chamber, and dry with warm air for 10 minutes. Locate the spots on the plate by spraying lightly with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry at 110° for 15 minutes: the R_F value of the principal spot obtained from the test solution corresponds to that obtained from the Standard

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution.
NORFLURANE	IMPURITIES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Organic Impurities*/*Table 2*: Change Line No. to: Peak Elution Order AND In *Halides*/*Figure 1*: Add label Flow Meter
CEFDINIR	IMPURITIES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Organic Impurities*/*Table 2*/footnote a: Change 1*N*-[(*Z*)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)acetyl]glycine. to: *N*-[(*Z*)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)acetyl]glycine.
AMIKACIN SULFATE	ASSAY	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Procedure*/*Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	Change C_U = concentration of amikacin in the *Sample solution* (mg/mL) to: C_U = concentration of Amikacin Sulfate in the *Sample solution* (mg/mL) In *Dissolution* ?711?/*Test for dutasteride*/*Tier 2*/*Medium*: Change 10 g/L of cetyltrimethylammonium bromide and 750,000 USP units of activity/mg of pepsin, purified in 0.1 N hydrochloric acid; 900 mL to: Dissolve 10 g of cetyltrimethylam

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								monium bromide and 1.6 g of pepsin, purified in 1000 mL of 0.1 N hydrochloric acid; 900 mL
SODIUM SALICYLATE	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?: Add USP Phenol RS
CEFDINIR FOR ORAL SUSPENSION	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?/USP Cefdinir Related Compound A RS: Change 413.43 to: 413.42 AND In *USP Reference Standards* ?11?/USP Cefdinir Related Compound B RS: Change C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{14}H_{13}N_4O_4S_2$ 365.41 to: $C_{14}H_{14}N_4O_4S_2$ 366.41
COLOR AND ACHROMICITY	METHOD II: INSTRUMENTAL (QUANTITATIVE) ASSESSMENT OF COLOR AND COLOR MATCHES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Table 5*: Change Sum 98.809 100.000 107.307 White point 98.811 100.000 107.304 to: Sum 94.809 100.000 107.307 White point 94.811 100.000 107.304
AZITHROMYCIN	IMPURITIES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Organic Impurities*/*Table 2*: Change 3'-*N*-Demethyl-3'-*N*-[(4-methylphenyl)sulfonyl]azithromycin[m] to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3?-*N*-{[4-(Acetylamino)phenyl]sulfonyl}-3?-demethylazithromycin[m] AND In *Table 2*/footnote m: Change (2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-Dideoxy-3-*C*-methyl-3-*O*-methyl-?-L-*ribo*-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[*N*-(4-methylphenylsulfonyl)-*N*-methylamino]-3,4,6-trideoxy-ß-D-*xylo*-hexopyranosyl]oxy]-1-oxa-6-az

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acyclopentadecan-15-one. to: (2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-Dideoxy-3-*C*-methyl-3-*O*-methyl-?-L-*ribo*-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[*N*-(4-acetamidophenylsulfonyl)-*N*-methylamino]-3,4,6-trideoxy-?-D-*xylo*-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
OLMESARTAN MEDOXOMIL	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?/*Test*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS								*5/Apparatus 2*: Change 50 rpm. Use peak vessels. to: 50 rpm. Use apex vessels.
CEFDINIR	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?/USP Cefdinir Related Compound A RS: Change 413.43 to: 413.42
AMOXICILLIN BOLUSES	IDENTIFICATION	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	Change *Application volume*, *Developing solvent system*, *Procedure*—Proceed as directed for the *Identification* test under *Amoxicillin Tablets*. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Application volume—5 µL. *Developing solvent system*—a mixture of methanol, chloroform, water, and pyridine (90:80:30:10). *Procedure*—Proceed as directed in *Thin-Layer Chromatographic Identification Test* <201>. Dry the plate with the aid of a current of warm air for 10 minutes. Locate the spots on the plate by spraying lightly with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								at 110° for 15 minutes.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?/USP Dihydrodutasteride RS: Change *N*-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5?-androst-1-ene-17?-carboxamide. to: *N*-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5?-androstane-17?-carboxamide.
Strychnine Sulfate	REAGENTS AND REFERENCE TABLES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Reagent Specifications*: Change CAS RN®: 60-41-3. to: CAS RN®: 60491-10-3.
MEASUREME	APPARATUS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Figure 2*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NT OF STRUCTURAL STRENGTH OF SEMISOLIDS BY PENETRO METRY								Change 66±0.25 Ø to: 65±0.25 Ø
DICLOFENAC SODIUM AND MISOPROSTOL DELAYED-RELEASE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?: Move *Test 2* after *Test 1*
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?/*Test 2*/*Acid stage*: Change **Acid stage standard solution:** (*L*/10) mg/mL of USP Pantoprazole Sodium RS from the *Standard stock solution* in *Acid stage medium*, where *L* is the label claim in mg/Tablet to: **Acid stage**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard solution: (*L*/10000) mg/mL of USP Pantoprazole Sodium RS from the *Standard stock solution* in *Acid stage medium*, where *L* is the label claim in mg/Tablet AND In *Dissolution* <711>/*Test 2*/*Buffer stage*: Change **Buffer stage standard solution:** (*L*/1000) of USP Pantoprazole Sodium RS where *L* is the label claim in mg/Tablet to: **Buffer stage standard**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CEFDINIR CAPSULES	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	**solution:** (*L*/1000) mg/mL of USP Pantoprazole Sodium RS from the *Standard stock solution* in *Buffer stage medium*, where *L* is the label claim in mg/Tablet In *USP Reference Standards* ?11?/USP Cefdinir Related Compound A RS: Change 413.43 to: 413.42 AND In *USP Reference Standards* ?11?/USP Cefdinir Related Compound B RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TELMISARTAN TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	$C_{14}H_{13}N_4O_4S_2$ 365.41 to: $C_{14}H_{14}N_4O_4S_2$ 366.41 In *Dissolution* ?711?/*Test 1*/*Analysis*: Change Determine the percentage of telmisartan ($C_{33}H_{30}N_4O_2$) dissolved: Result = (A_U × C_S × V × 100)/(A_S × D × L) to: Calculate the percentage of the labeled amount of telmisartan ($C_{33}H_{30}N_4O_2$) dissolved: Result = (A_U/A_S) × C_S × V × D × (1/L) × 100 AND Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_S = concentration of the *Standard solution* (mg/mL) to: C_S = concentration of USP Telmisartan RS in the *Standard solution* (mg/mL) AND In *Dissolution* ?711?/*Test 2*/*Analysis*: Change r_U = peak response from the *Sample solution* r_S = peak response from the *Standard solution* to: r_U = peak response of telmisartan from the *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution r_S = peak response of telmisartan from the *Standard solution* AND In *Dissolution* ?711?/*Test 3*/*Analysis*: Change C_S = concentration of the *Standard solution* (mg/mL) to: C_S = concentration of USP Telmisartan RS in the *Standard solution* (mg/mL)
METHYLBENZETHONIUM CHLORIDE	ASSAY	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	In *Procedure*/*Analysis*: Change Calculate the percentage of methylbenzethoni

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								um chloride ($C_{28}H_{44}ClNO_2 \cdot H_2O$) in the portion of Methylbenzethonium Chloride taken: to: Calculate the percentage of methylbenzethonium chloride ($C_{28}H_{44}ClNO_2$) in the portion of Methylbenzethonium Chloride taken:
AMOXICILLIN FOR INJECTABLE SUSPENSION	Identification	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	Change Prepare a test solution containing the equivalent of 4 mg of amoxicillin per mL by adding 0.1 N hydrochloric acid to Amoxicillin for Injectable Suspension. Allow the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution to stand for 5 minutes before use: the solution responds to the *Identification* test under *Amoxicillin Capsules*. to: Prepare a test solution containing the equivalent of 4 mg of amoxicillin per mL by adding 0.1 N hydrochloric acid to Amoxicillin for Injectable Suspension. Allow the solution to stand for 5 minutes before use. Prepare a Standard solution of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Amoxicillin RS in 0.1 N hydrochloric acid containing 4 mg per mL. Use within 10 minutes after preparation. Apply separately 5 µL of each solution on a thin-layer chromatographic plate coated with a 0.25-mm layer of chromatographic silica gel mixture (see *Chromatography* <621>). Place the plate in a suitable chromatographic chamber, and develop the chromatogram in a solvent system consisting of a mixture of methanol,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chloroform, water, and pyridine (90:80:30:10). When the solvent front has moved about three-fourths of the length of the plate, remove the plate from the chamber, and dry with warm air for 10 minutes. Locate the spots on the plate by spraying lightly with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry at 110° for 15 minutes: the R_F value of the principal spot obtained from the test solution corresponds to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								that obtained from the Standard solution.
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STRENGTH	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	In *Vitamin A, Method 3*/*Analysis*: Change C_S = concentration of retinyl acetate ($C_{23}H_{32}O_2$) from USP Vitamin A RS in the *Standard solution* (?g/mL) to: C_S = concentration of retinyl acetate ($C_{22}H_{32}O_2$) from USP Vitamin A RS in the *Standard solution* (?g/mL)
UREA	SPECIFIC TESTS	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	In *Alcohol-Insoluble Matter*/*Sample solution*: Change 100 mg/mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Urea dissolved in warm alcohol to: Dissolve 5.0 g of Urea in 50 mL of warm alcohol. AND In *Alcohol-Insoluble Matter/Analysis*: Change If any insoluble residue remains, pass the *Sample solution* through a tared filter, wash the residue and the filter with 20 mL of warm alcohol per 50 mL of *Sample solution*, and dry at 105° for 1 h. to: If any insoluble residue remains, pass

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TELMISARTAN ASSAY TABLETS		*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	the *Sample solution* through a tared filter, wash the residue and the filter with 20 mL of warm alcohol, and dry at 105° for 1 h. In *Procedure*/*System suitability*/*Suitability requirements*: Change **Resolution:** NLT 3 between telmisartan and telmisartan related compound A **Tailing factor:** NMT 2.0 for the telmisartan peak **Capacity factor:** NLT 1.5 **Relative standard**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								deviation: NMT 2.0% to: **Resolution:** NLT 3 between telmisartan and telmisartan related compound A **Tailing factor:** NMT 2.0 for telmisartan **Relative standard deviation:** NMT 2.0% for telmisartan
PARTICLE SIZE ANALYSIS BY DYNAMIC LIGHT SCATTERING	GLOSSARY	*USPNF Online*	Online	27-Oct-2023	1-May-2024	*NA*	*NA*	In *Average particle diameter*: Change expressed in nanometers. to: expressed in meters. AND In *Viscosity*: Change in millipascal-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								seconds (mPa?s). to: in pascal-seconds (Pa?s).
OIL-SOLUBLE VITAMINS CAPSULES	STRENGTH	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	In *Vitamin A, Method 3/Analysis*: Change C_S = concentration of retinyl acetate ($C_{23}H_{32}O_2$) from USP Vitamin A RS in the *Standard solution* (?g/mL) to: C_S = concentration of retinyl acetate ($C_{22}H_{32}O_2$) from USP Vitamin A RS in the *Standard solution* (?g/mL)
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS	ASSAY	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	In *Procedure/System suitability/Tailing*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								factor: Change NMT 2.0, *System suitability solution* to: NMT 2.0 for pantoprazole, *System suitability solution*
TAMSULOSIN HYDROCHLORIDE CAPSULES	IMPURITIES	*USPNF Online*	Online	29-Sep-2023	1-Oct-2023	*NA*	*NA*	In *Organic Impurities*/*System suitability*: Change **Sample:** *Standard solution* [Note—The relative retention times for methoxy tamsulosin, tamsulosin, ethoxyphenoxy ethyl bromide, and desethoxy tamsulosin are 0.73, 1.00, 1.80, and 2.80,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								respectively.] **Suitability requirements** **Tailing factor:** NMT 2.0 **Relative standard deviation:** NMT 5.0% **Signal-to-noise ratio:** NLT 10 to: **Samples:** *Standard solution* and *Sensitivity solution* [Note—The relative retention times for methoxy tamsulosin, tamsulosin, ethoxyphenoxy ethyl bromide, and desethoxy tamsulosin are 0.73, 1.00, 1.80, and 2.80, respectively.]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Suitability requirements **Tailing factor:** NMT 2.0, *Standard solution* **Relative standard deviation:** NMT 5.0%, *Standard solution* **Signal-to-noise ratio:** NLT 10, *Sensitivity solution*
DIGOXIN TABLETS	ASSAY	*USPNF Online*	Online	29-Sep-2023	1-Oct-2023	*NA*	*NA*	In *Procedure/Analysis*: Change C_U = nominal concentration of in the *Sample solution* (µg/mL) to: C_U = nominal concentration of digoxin in the *Sample solution* (µg/mL)
DIVALPROEX	PERFORMANC	*USPNF Online*	Online	29-Sep-2023	1-Oct-2023	*NA*	*NA*	In *Dissolution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM EXTE E TESTS NDED-RELEASE TABLETS								?711?/*Test 8*/*Tolerances*: Change The percentage of the labeled amount of valproic acid ($C_8H_{16}O_2$) dissolved at the times specified conform to *Dissolution* <711>, *Acceptance Table 1*. to: The percentage of the labeled amount of valproic acid ($C_8H_{16}O_2$) dissolved at the times specified conform to *Dissolution* <711>, *Acceptance Table 2*.
UREA C 13	IMPURITIES	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Isotopic Purity*/*Chromatographi*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								c system: Change **Flow rate**: Flow rate to: **Flow rate**: 1 mL/min
BLACK CUMIN SEED THYMOQUINONE OIL	SPECIFIC TESTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Fats and Fixed Oils* ?401?, *Procedures*, *Fatty Acid Composition*/*Table 2*: Change Linoleic to: Linoleic acid
CRANBERRY FRUIT DRY JUICE	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *USP Reference Standards* ?11?: Change USP Procyanidin A_2 RS to: USP Procyanidin A2 RS
ZIPRASIDONE	IMPURITIES	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Organic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSULES								*Impurities/Solution B*: Change potassium hydroxide to: potassium hydroxide solution AND In *Organic Impurities/Analysis*: Change 449.40 to: 449.39
VALGANCICLOVIR HYDROCHLORIDE	IMPURITIES	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Organic Impurities/Table 3*/footnote c: Change 2-[(2-Amino-6-oxo-1,6-dihydro-9*H*-purin-9-yl)methoxy]-2-hydroxypropyl methyl-L-valinate hydrochloride. to: 3-[(2-Amino-6-o

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								xo-1,6-dihydropurin-9-yl)methoxy]-2-hydroxypropyl L-valinate hydrochloride.
ARIPIPRAZOLE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Dissolution <711>/Test 1/ Procedure/ Chromatographic procedure/Analysis*: Change Result = $(R_U/R_S) \times C_S \times V \times (1/L) \times 100$ to: Result = $(R_U/R_S) \times C_S \times V \times D \times (1/L) \times 100$ AND Add *D* = dilution factor of the *Sample solution*, 2
CRANBERRY FRUIT DRY	IDENTIFICATION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *A./Standard solution B*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
JUICE								Change USP Procyanidin A_2 RS to: USP Procyanidin A2 RS AND In *A./System suitability/Suitability requirements/ Derivatization reagent B/White light*: Change *Standard solution B* exhibits two brown bands in the upper-half section corresponding to procyanidin A_2 and epicatechin. *Standard solution C* exhibits two

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								brown bands in the upper-half section corresponding in R_F and color to procyanidin A_2 and epicatechin in *Standard solution B*. *Standard solution C* also exhibits a series of faint or indistinct brown bands of differing intensities below procyanidin A_2 in the lower-half section. to: *Standard solution B* exhibits two brown bands in the upper-half section corresponding to procyanidin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								A2 and epicatechin. *Standard solution C* exhibits two brown bands in the upper-half section corresponding in R_F and color to procyanidin A2 and epicatechin in *Standard solution B*. *Standard solution C* also exhibits a series of faint or indistinct brown bands of differing intensities below procyanidin A2 in the lower-half section. AND In *A./ Acceptance criteria/*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Derivatization reagent B/*White light*: Change The *Sample solution* exhibits two faint brown bands corresponding in R_F to procyanidin A_2 and epicatechin in *Standard solution B*. The *Sample solution* also exhibits a series of faint or indistinct brown bands of differing intensities in the lower-half section, corresponding to the same bands in *Standard solution C*. No bands corresponding in R_F to epigallo cate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chin-3-*O*-gallate, procyanidin B_2, or procyanidin B_1 appear below procyanidin A_2. to: The *Sample solution* exhibits two faint brown bands corresponding in R_F to procyanidin A2 and epicatechin in *Standard solution B*. The *Sample solution* also exhibits a series of faint or indistinct brown bands of differing intensities in the lower-half section, corresponding to the same bands in *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution C. No bands corresponding in R_F to epigallocatechin-3-*O*-gallate, procyanidin B2, or procyanidin B1 appear below procyanidin A2. AND In *C./Acceptance criteria/Profile at 520 nm*: Change cyanidin-3-*O*-arabinose, to: cyanidin-3-*O*-arabinoside, AND In *C./Acceptance criteria/Profile at 520 nm*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								peon idin-3-*O* -arabinose to: peon idin-3-*O* -arabinoside
ZIPRASIDONE CAPSULES	ASSAY	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Procedure/Analysis*: Change 449.40 to: 449.39
AZITHROMYCIN	IMPURITIES	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Organic Impurities/Table 2*: Change: 3?-*N* -{[4-(Acetylamino)phenyl]sulfonyl}-3?-demethylazithromycin[m] to: 3'-*N* -Demethyl-3'-*N* -[(4-methylphenyl)sulfonyl]azithromycin[m] AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								In *Organic Impurities*/*Table 2*/footnote m: Change (2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-Dideoxy-3-*C*-methyl-3-*O*-methyl-?-L-*ribo*-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[*N*-(4-acetamidophenylsulfonyl)-*N*-methylamino]-3,4,6-trideoxy-?-D-*xylo*-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DEXTROMETH ORPHAN HYDROBROMIDE ORAL SOLUTION	*Assay*	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	(2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-Dideoxy-3-*C*-methyl-3-*O*-methyl-?-L-*ribo*-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[*N*-(4-methylphenylsulfonyl)-*N*-methylamino]-3,4,6-trideoxy-ß-D-*xylo*-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. In *Chromatographic system* and *Procedure*: Change *C* is the concentration,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								in mg per mL, of USP Dextromethorphan Hydrobromide RS, on the anhydrous basis, in the *Standard preparation*; to: *C* is the concentration, in mg per mL, of USP Dextromethorphan Hydrobromide RS in the *Standard preparation*;
SODIUM ALGINATE	ASSAY	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Procedure/Analysis*: Change Result = $(V_2 \times N \times W_E)/(W \times D)$ to: Result = $(V_2 \times N \times W_E \times 10)/(W \times D)$

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »